Exemestane vs Kisspeptin
FDA Approved vs Emerging
synergistic Mechanism-based · 49% Kisspeptin helps manage estrogen conversion from Exemestane. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Exemestane Kisspeptin
Weight 296.40 Da 1,213.42 Da (KP-10) / 6,087 Da (KP-54)
Half-life ~24 hours ~4 minutes (KP-10), ~28-32 minutes (KP-54)
Chain — 10-54 amino acids
Type Steroidal aromatase inhibitor (irreversible, suicide inhibitor) Neuropeptide family (RFamide)
Key Benefits
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Kisspeptin
01 Potent reproductive hormone stimulation (LH/FSH)
02 Restoration of natural testosterone production
03 Fertility enhancement
04 Sexual function support
05 Hypogonadism treatment potential
Dosing Protocols
Exemestane
12.5mg EOD or 25mg E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
Kisspeptin
100-200 mcg per injection / Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Gonadotropin stimulation 100-200mcg Single dose or 2-3x weekly
Fertility support 0.4-1.0 nmol/kg (50-150mcg) As directed by physician
Sexual function (clinical) 1 nmol/kg/h 75-minute IV infusion
Side Effects
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Kisspeptin
Minimal acute side effects reported
Potential mild cardiovascular effects
Contraindications
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Not recommended during pregnancy or breastfeeding
Caution with cardiovascular disease history
Daily dosing causes receptor desensitization
Research Evidence
Exemestane Kisspeptin
Status FDA Approved Emerging
References 5 studies 4 studies
Latest — 2025
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.